Epcoritamab clinical trials
Also written GEN3013 and Epkinly.
How each study uses epcoritamab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the epcoritamab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 19 May 2023 · EPKINLY · BLA 761324 (FDA, Drugs@FDA)
- European Union
- 22 Sept 2023 · Tepkinly · EMEA/H/C/005985 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
56 studies that test it; most in 2025 (17); 1 more planned to start later
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 5 |
| 2023 | 5 |
| 2024 | 10 |
| 2025 | 17 |
| 2026 | 14 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 13 · Other 44
Genmab (13) · City of Hope Medical Center (4) · The Lymphoma Academic Research Organisation (3) · National Heart, Lung, and Blood Institute (NHLBI) (2) · M.D. Anderson Cancer Center (2) · Stichting Hemato-Oncologie voor Volwassenen Nederland (2) · Reid Merryman, MD (2) · Memorial Sloan Kettering Cancer Center (2)
Often tested with
Tested in the same studies.
Lenalidomide (9) · Rituximab (7) · Oxaliplatin (3) · Gemcitabine (3) · Ibrutinib (3) · Venetoclax (3) · Pirtobrutinib (2) · Loncastuximab tesirine (2)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 16
Studies that test epcoritamab.
- Nov 2026Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCLPhase 2 · Australasian Leukaemia and Lymphoma Group
- Dec 2026Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative DisordersPhase 1 · Timothy Voorhees
- Feb 2027Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell LymphomaPhase 2 · Reem Karmali
- Mar 2027A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular LymphomaPhase 2 · Genmab
- Apr 2027Epcoritamab in Previously Treated WMPhase 2 · Gottfried von Keudell, MD PhD
- May 2027A Phase 2 Study of Epcoritamab in Patients With Follicular Lymphoma and Marginal Zone Lymphoma Not Accomplishing a Complete Response With Upfront TherapyPhase 2 · Beth Israel Deaconess Medical Center
- Jul 2027Epcoritamab in Chronic Lymphocytic Leukemia and Richter SyndromePhase 1 · National Heart, Lung, and Blood Institute (NHLBI)
- Jul 2027Study of Epcoritamab as a Consolidation Therapy in CLL/SLLPhase 2 · Zulfa Omer
- Aug 2027Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular LymphomaPhase 2 · City of Hope Medical Center
- Aug 2027Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin LymphomaPhase 1/2 · Yazeed Sawalha
Studies
Open first, then newest update. How each study uses epcoritamab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 57
- Epcoritamab as Consolidative Therapy for Waldenstr(SqrRoot)(Delta)m Macroglobulinemia (WM) Treated With a Bruton Tyrosine Kinase Inhibitor (BTKi)Not yet recruitingPhase 2National Heart, Lung, and Blood Institute (NHLBI)NCT07882173Written as epcoritamab
- A Phase 2 Study of Epcoritamab in Patients With Follicular Lymphoma and Marginal Zone Lymphoma Not Accomplishing a Complete Response With Upfront TherapyRecruitingPhase 2Beth Israel Deaconess Medical CenterNCT06510361Written as Epcoritamab
- Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKINot yet recruitingPhase 2University of California, IrvineNCT07819214Written as Epcoritamab
- Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell LymphomaRecruitingPhase 2Vijendra SinghNCT05852717Written as Epcoritamab
- A Prospective, Open-label, Randomized, Multicenter Phase-III Trial to Evaluate the Efficacy of Pirtobrutinib and Epcoritamab Compared With R-(Mini)-CHOP for Treatment of Patients With DLBCL-type Richter TransformationRecruitingPhase 2German CLL Study GroupNCT07917780Written as Epcoritamab
- Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphomaNot yet recruitingPhase 2M.D. Anderson Cancer CenterNCT07783594Written as Epcoritamab
- Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin LymphomaRecruitingPhase 2University of WashingtonNCT07097363Written as Epcoritamab
- Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK StudyNot yet recruitingPhase 2AIDS Malignancy ConsortiumNCT07662928Written as Epcoritamab
- Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell LymphomaRecruitingPhase 2University of MiamiNCT06919939Written as Epcoritamab
- Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)RecruitingPhase 2Izidore Lossos, MDNCT06796998Written as Epcoritamab
- Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma With Pirtobrutinib in Combination With Epcoritamab if the Disease Comes Back After Previous Treatment.Not yet recruitingPhase 2Stichting Hemato-Oncologie voor Volwassenen NederlandNCT07860775Written as pirtobrutinib combined with epcoritamab
- Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLLRecruitingPhase 1/2Stichting Hemato-Oncologie voor Volwassenen NederlandNCT05791409Written as Epcoritamab
- Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin LymphomaNot yet recruitingPhase 2Carrie Ho, MDNCT07588698Written as Epcoritamab
- Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell LymphomaRecruitingPhase 2Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaNCT07126236Written as Epcoritamab
- Epco, Zanu, Ritux for R/R FL or MZLRecruitingPhase 2Reid Merryman, MDNCT06563596Written as Epcoritamab
- Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell LymphomaRecruitingPhase 2M.D. Anderson Cancer CenterNCT06045247Written as Epcoritamab
- Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative DisordersRecruitingPhase 1Timothy VoorheesNCT06672705Written as Epcoritamab
- Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell TherapyNot yet recruitingPhase 2The Lymphoma Academic Research OrganisationNCT07814001Written as Epcoritamab
- Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaRecruitingPhase 2City of Hope Medical CenterNCT07365306Written as Epcoritamab
- Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin LymphomaRecruitingPhase 1/2Yazeed SawalhaNCT06536049Written as Epcoritamab
See all 57 studies that test epcoritamab →
Given beside what is tested · 5 — epcoritamab is usual care or a partner of the new treatment
- A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin LymphomasRecruitingPhase 1/2Bristol-Myers SquibbNCT06090539Written as Epcoritamab
- Bispecific Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Cell LymphomasRecruitingPhase 2National Research Center for Hematology, RussiaNCT07883135Written as Epcoritamab
- A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)Active, not recruitingPhase 3GenmabNCT05578976Written as Epcoritamab
- A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin LymphomaActive, not recruitingPhase 2GenmabNCT05283720Written as Epcoritamab
- First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin LymphomasTerminatedPhase 1/2GenmabNCT04358458Written as Epcoritamab
What changed recently
From the registry's own updates since Oct 18, 2026.
Results posted2
- A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in ChinaNov 10, 2026NCT07226752
- A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)Nov 3, 2026NCT04628494
Newly registered2
- A Prospective, Open-label, Randomized, Multicenter Phase-III Trial to Evaluate the Efficacy of Pirtobrutinib and Epcoritamab Compared With R-(Mini)-CHOP for Treatment of Patients With DLBCL-type Richter TransformationNov 5, 2026NCT07917780
- Epcoritamab as Consolidative Therapy for Waldenstr(SqrRoot)(Delta)m Macroglobulinemia (WM) Treated With a Bruton Tyrosine Kinase Inhibitor (BTKi)Oct 20, 2026NCT07882173
Codes
What other systems call epcoritamab · ClinicalTrials.gg INT002168
- MeSH (NLM) C000731938epcoritamabOne source NLM
- UNII (FDA) D6OMY2L0WAEPCORITAMABConfirmed FDA, NLM, Wikidata
- Wikidata Q119025940epcoritamabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C163022EpcoritamabOne source FDA
- DrugBank DB16672One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731938 | epcoritamab | One source NLM |
| UNII (FDA) | D6OMY2L0WA | EPCORITAMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q119025940 | epcoritamab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C163022 | Epcoritamab | One source FDA |
| DrugBank | DB16672 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.